Gapping up
In reaction to strong earnings/guidance: APPS +12.1%, (guidance) NQ +10.9%, HIIQ +10%, SCVL +10%, GES +9%, SFS +8.4%, FLML +6.4%, (guidance) CAPR +4.9%, VNCE +2.9%, CTAS +2.3%, MCS +2.3%, LEN +2%, MIK +1.2%, TLYS +0.6%
Other news: FOLD +22.8% (announces positive global regulatory updates from EMA and FDA meetings for Fabry Monotherapy), CBMX +14.4% (entered into a contractual agreement with InterWest Health), SMLR +12.3% (announces receipt of 510(k) marketing clearance from the FDA for its next generation peripheral artery disease testing system), HRTX+10.8% (announces positive results from a Phase 1 clinical study of HTX-011), CNDO +8.7% (announces the execution of an exclusive license agreement with NeuPharma), SYN +7.1% (announces positive pharmacokinetics results from both the Phase 1a and 1b studies of SYN-004), WYY +3.1% (announces that its subsidiary iSYS LLC has received a Task Order renewal from the Department of Homeland Security Headquarters and a new Task Order from OBIM ), MTL +2.4% (follow-on strength from yday), RAD +2% (announced intention to offer $1.8 billion aggregate principal amount of senior unsecured notes due 2023 in connection with acquisition of EnvisionRx), LBIO +2% (favorable commentary on Wednesday's Mad Money), ESPR +1.2% (prices 1,750,000 shares of its common stock at $100.00 per share), PLKI +1% (favorable commentary on Wednesday's Mad Money), RCPT +0.9% (favorable commentary on Wednesday's Mad Money), CELG +0.8% (announced that results from a phase 2 trial of three doses of GED-0301 in patients with active Crohn's disease were published in the March 19 issue of The New England Journal of Medicine)
Analyst comments: BIIB +1.2% (target raised to $500 from $400 at Credit Suisse), CYT +1.1% (upgraded to Buy from Neutral at Citigroup), WYNN +0.9% (initiated with a Buy at Brean Capital), CERN +0.8% (upgraded to Outperform at Robert W. Baird
)
In reaction to strong earnings/guidance: APPS +12.1%, (guidance) NQ +10.9%, HIIQ +10%, SCVL +10%, GES +9%, SFS +8.4%, FLML +6.4%, (guidance) CAPR +4.9%, VNCE +2.9%, CTAS +2.3%, MCS +2.3%, LEN +2%, MIK +1.2%, TLYS +0.6%
Other news: FOLD +22.8% (announces positive global regulatory updates from EMA and FDA meetings for Fabry Monotherapy), CBMX +14.4% (entered into a contractual agreement with InterWest Health), SMLR +12.3% (announces receipt of 510(k) marketing clearance from the FDA for its next generation peripheral artery disease testing system), HRTX+10.8% (announces positive results from a Phase 1 clinical study of HTX-011), CNDO +8.7% (announces the execution of an exclusive license agreement with NeuPharma), SYN +7.1% (announces positive pharmacokinetics results from both the Phase 1a and 1b studies of SYN-004), WYY +3.1% (announces that its subsidiary iSYS LLC has received a Task Order renewal from the Department of Homeland Security Headquarters and a new Task Order from OBIM ), MTL +2.4% (follow-on strength from yday), RAD +2% (announced intention to offer $1.8 billion aggregate principal amount of senior unsecured notes due 2023 in connection with acquisition of EnvisionRx), LBIO +2% (favorable commentary on Wednesday's Mad Money), ESPR +1.2% (prices 1,750,000 shares of its common stock at $100.00 per share), PLKI +1% (favorable commentary on Wednesday's Mad Money), RCPT +0.9% (favorable commentary on Wednesday's Mad Money), CELG +0.8% (announced that results from a phase 2 trial of three doses of GED-0301 in patients with active Crohn's disease were published in the March 19 issue of The New England Journal of Medicine)
Analyst comments: BIIB +1.2% (target raised to $500 from $400 at Credit Suisse), CYT +1.1% (upgraded to Buy from Neutral at Citigroup), WYNN +0.9% (initiated with a Buy at Brean Capital), CERN +0.8% (upgraded to Outperform at Robert W. Baird
)